Page 31 - Shimadzu Journal vol.9 Issue1

Latest topics 2

Latest topics 2

Shimadzu (Asia Pacific) &

Changi General Hospital (CGH) jointly

launch centre to conduct mass

spectrometry-based clinical testing and

research for personalised treatment

The Shimadzu-CGH Clinomics Centre (SC ) aims technologies and instruments that will enhance the standard of care
3
to improve turn-around time and clinical diag- for our patients.”
nostic accuracy of diseases such as hypertension As Shimadzu we are committed to using our years of experi-
and other endocrine conditions in adults ence in Analytical and Medical technologies towards Advanced
On 27 January 2021, Singapore—The Shimadzu–CGH Clinomics Healthcare initiatives. Mr. Tetsuya Tanigaki, Managing Director,
Centre (SC ), a public-private partnership by Changi General Shimadzu (Asia Pacific) Pte Ltd, highlighted, “Excellence in Science
3
Hospital (CGH) and Shimadzu (Asia Pacific), was officially opened is not only a motto but a way of life in the Shimadzu Family. And
by the Guest of Honour, Deputy Prime Minister of Singapore it is with this philosophy that we, along with CGH, are powering
Heng Swee Keat. A satellite laboratory of CGH, the initial SC the SC lab with futuristic technologies such as mass spectrometry
3
3
operations will focus on developing and validating various clinical and Analytical Intelligence among several others, to ensure that we
applications and research to improve clinical diagnostics, which deliver more accurate and faster outcomes to patients. This Centre
lead to better clinical care for patients with hypertension and other is an example of how we can collaborate to establish a pioneer-
chronic diseases. ing partnership for Advanced Healthcare. This is the first time that
Professor Ng Wai Hoe, Chief Executive Officer, CGH, very Shimadzu is working with a public hospital to establish a Clinomics
well stated the need and relevance of such collaborations, “The Laboratory in Singapore. Our efforts will certainly transform the
coming together of the clinical and research expertise of CGH and healthcare landscape of not only Singapore and the Asia Pacific
SingHealth with Shimadzu’s diagnostic and analytical capabilities region but also of the world.”
3
will contribute to medical care and treatment in Singapore. At SC ,
Top image: DPM Heng witnessed the signing of the Research Collaboration
we will co-create clinical applications through mass spectrometry Agreement between CGH and Shimadzu (Asia Pacific)

Shimadzu Journal vol.9 Issue1 30